Welcome to UCL Cancer Institute
The UCL Cancer Institute is the hub for cancer research at University College London, one of the World's leading universities. The Institute draws together over 300 talented scientists who are working together to translate research discoveries into developing kinder, more effective therapies for cancer patients. If you are thinking about studying with us, applications to our flagship MSc Cancer postgraduate programme will open soon for September 2018 entry, plus new undergraduate degree BSc Cancer Biomedicine starting September 2018 is now open to application.
News and features
Researchers from the UCL Cancer Institute and the specialist healthcare company BTG plc have begun the first clinical trial of an experimental treatment for liver cancer using X-ray imageable microscopic beads loaded with a targeted anti-cancer drug placed directly in the liver.
Published: Oct 11, 2017 12:17:24 PM
The highly anticipated results from the ARIEL3 clinical trial, evaluating use of rucaparib among women with advanced ovarian cancer, have been published in The Lancet. According to study data, maintenance therapy with rucaparib (Rubraca, Clovis Oncology) significantly extended progression-free survival among women with platinum-sensitive recurrent ovarian cancer.
Published: Oct 1, 2017 2:29:11 PM
A University College Hospital prostate cancer patient has undergone diagnosis using hyperpolarised Magnetic Resonance Imaging (MRI) as part of a UCL clinical trial. Led by Dr Shonit Punwani, the trial aims to develop more accurate and personalised treatment for cancer.
Published: Aug 23, 2017 4:17:30 PM
A subgroup of patients with osteosarcoma - a form of bone cancer - could be helped by an existing drug, suggest scientists from the Wellcome Trust Sanger Institute and their collaborators at University College London Cancer Institute and the Royal National Orthopaedic Hospital NHS Trust.
Published: Jun 23, 2017 1:45:15 PM
A new drug trialled at the NIHR/Wellcome UCLH Clinical Research Facility (CRF) could help improve outcomes for women with advanced cervical cancer. More than a quarter the participants in trials of the immunotherapy drug Nivolumab experienced significant tumour shrinkage or complete remission.
Published: Jun 16, 2017 6:54:00 PM
Support our work
Help us to continue the research that will lead to the breakthroughs in therapies for cancer patients. Support us >
Action for equality and diversity
UCL Cancer Institute is proud to hold an Athena SWAN silver award in recognition of our commitment to advancing equality, diversity and inclusion.